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979 
SURPASSING THE MATERIAL:1 THE HUMAN 
RIGHTS IMPLICATIONS OF INFORMED 
CONSENT IN BIOPROSPECTING CELLS 
DERIVED FROM INDIGENOUS PEOPLE GROUPS 
INTRODUCTION 
From the time man and woman first walked in the Garden of Eden, the 
world’s resources have lain at their feet.2 Although they soon erected city 
walls and drew country borders, human beings used natural resources with 
generous liberality, considering all flora3 and fauna4 their rightful 
inheritance. Using this principle, called the Common Heritage of 
Humankind,5 biological diversity prospectors,6 or bioprospectors, plunder 
the genetic wealth of the world’s resources. With the rapid development 
and far-reaching effects of technology, biological diversity7 has suffered 
 
 
 1. Ovid described the transformative effect of fantastical artwork on simple walls with the 
words “[m]ateriam superbat opus” (the workmanship surpassed the material). THOMAS BULFINCH, 
BULFINCH ’S MYTHOLOGY 41, 333 (The Modern Library 1998) (1855). Considering how human cell 
research invariably provokes questions about the human condition, the description is an apt one in this 
context. 
 2. God said: 
I give you every seed-bearing plant on the face of the whole earth and every tree that has fruit 
with seed in it . . . And to all the beasts of the earth and all the birds of the air and all the 
creatures that move on the ground—everything that has the breath of life in it—I give every 
green plant for food.  
Genesis 1:29-30 (New International Version). 
 3. Flora denotes “[p]lants as a whole, [especially] those of a specific region or season.” 
WEBSTER’S II NEW RIVERSIDE DICTIONARY  269 (2d ed. 1984). 
 4. Fauna denotes “[a]nimals as a group, [especially] of a given time or region.” Id. at 254. 
 5. See infra  note 26 and accompanying text (describing the Common Heritage of Humankind 
and its role in an international context). See infra  note 27 and accompanying text (arguing that 
humankind has an inherent interest in the world’s genetic resources). 
 6. Biodiversity prospectors are scientists who extract valuable cells from the biodiverse flora 
and fauna of developing countries to further scientific research and manufacture commercially viable 
products. Biodiversity prospecting, or bioprospecting, is the collection of biologically diverse 
resources. See Christopher J. Hunter, Sustainable Bioprospecting: Using Private Contracts and 
International Legal Principles and Policies to Conserve Raw Medicinal Materials, 25 B.C. ENVTL. 
AFF. L. REV. 129, 131 (1997). 
 7. Biological diversity, or biodiversity, is the “variability among living organisms from all 
sources including, inter alia, terrestrial, marine and other aquatic ecosystems and the ecological 
complexes of which they are part . . . includ[ing] diversity within species, between species and of 
ecosystems.” United Nations Conference on Environment and Development: Convention on 
Biological Diversity, June 5, 1992, 31 I.L.M. 818, 823 [hereinafter Biodiversity Convention]. See 
PHILIPPE SANDS, PRINCIPLES OF INTERNATIONAL ENVIRONMENTAL LAW VOL. 1, at 368 (1995) 
(describing three kinds of biodiversity: genetic diversity, species diversity, and ecosystem diversity); 
Hunter, supra note 6, at 133. See also  BIODIVERSITY AND THE LAW xix (William J. Snape III ed., 
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from this philosophy.8 
When it became evident that private companies from developed 
countries were earning massive profits by exploiting natural resources 
from developing countries with little or no positive return for the source 
countries,9 the adequate compensation of indigenous people and the 
preservation of the biodiverse resources of developing countries through 
sustainable development became an international concern. In response to 
this concern, the Biodiversity Convention, an agreement that included 
provisions for the compensation of source countries for the use of their 
natural resources, entered into force in 1993.10 A year later, the Trade-
Related Aspects of Intellectual Property Rights (TRIPS Agreement), a part 
of the General Agreement on Tariffs and Trade (GATT) Multilateral Trade 
Negotiations known as the Uruguay Round,11 provided significant 
measures to encourage world trade through progressive intellectual 
property protection.12 
This Note addresses the role of informed consent and adequate 
compensation in the problematic practice of patenting cell-lines derived 
 
 
1996) (stating simply that “biodiversity is life”). 
 8. See discussion infra  Part I.A (giving examples of U.S.  biotechnology companies which 
extracted the genetic resources of developing countries and indigenous people groups without 
adequate compensation). 
 9. See Hunter, supra note 6, at 139. The exploitation of indigenous people groups includes the 
uncompensated use of indigenous knowledge as well as the extraction of plant, animal, and human 
cells for scientific research purposes. Id. See also Laurie Anne Whitt, Indigenous Peoples, Intellectual 
Property & the New Imperial Science, 23 OKLA. CITY U. L. REV. 211 (1998) (characterizing the 
commodification of cell-lines derived from indigenous peoples as biocolonialism, a “means of 
extending empire” through the privatization of genetic property). This Note focuses on the 
uncompensated use of human cells derived from indigenous people groups.  
 10. Biodiversity Convention, supra  note 7. See discussion infra  Part III (regarding inability of the 
Biodiversity Convention to adequately address the informed consent issue of U.S. biotech companies 
who extract cells from indigenous people groups).  
 11. General Agreement on Tariffs and Trade—Multilateral Trade Negotiations (The Uruguay 
Round): Agreement on Trade-Related Aspects of Intellectual Property Rights, Including Trade in 
Counterfeit Goods, Dec. 15, 1993, 33 I.L.M. 81 [hereinafter TRIPS Agreement]. See discussion infra 
Part III (addressing the utility of international intellectual property rights protection versus that of 
human rights legal instruments with regard to safeguarding bioprospecting activities on indigenous 
people groups).  
 12. See Charles R. McManis, The Interface Between International Intellectual Property and 
Environmental Protection: Biodiversity and Biotechnology, 76 WASH . U. L.Q. 255 (1998) (discussing 
the fundamental conflict between the Biodiversity Convention and the TRIPS Agreement in protecting 
the world’s resources). The TRIPS Agreement sets minimum procedural standards of intellectual 
property enforcement and prescribes national treatment. Under the TRIPS Agreement, nations have the 
obligation to extend the same kind of intellectual property protection to foreigners as is given to their 
own nationals. INTERNATIONAL INTELLECTUAL PROPERTY ANTHOLOGY 9 (Anthony D’Amato & Doris 
Estelle Long eds., 1996). See also TRIPS Agreement, supra  note 11, at art. 3 (providing for national 
treatment, the requirement that a state party extend the same intellectual property protection to 
members of other state parties that it extends to its own nationals). 
https://openscholarship.wustl.edu/law_lawreview/vol78/iss3/6
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from indigenous people groups of developing countries. In its discussion, 
this Note maintains that the international intellectual property protection 
afforded by the Biodiversity Convention and the TRIPS Agreement are 
not sufficient to protect indigenous people groups from bioprospectors 
who fail to obtain informed consent. These bioprospectors subject the 
members of indigenous people groups to the indignities of involuntary 
commodification, thereby infringing fundamental human rights.13 
Consequently, this Note proposes that the United States enact domestic 
legislation in order to implement its human rights obligations under 
various international law instruments to which it is a party.14 Instead of 
sacrificing the dignity of human beings for economic gain, the United 
States would make a valuable contribution toward establishing a jus 
cogens norm15 safeguarding the rights of indigenous people groups 
subjected to bioprospecting activities.16 
Part I of this Note addresses the background and history of 
bioprospecting, including the development of property rights in human 
genetic resources, the utility of cell-lines derived from human cells, and 
the mechanics of the patenting process. This section also includes a 
historical treatment of the growing implications of bioprospecting. Part II 
discusses the Biodiversity Convention and the TRIPS Agreement. Part III 
 
 
 13. See discussion infra  Part V (addressing how a lack of informed consent violates the 
fundamental human rights contained in various international legal instruments). See also  text 
accompanying note 113. 
 14. See Universal Declaration of Human Rights, G.A. Res. 217A (III), U.N. GAOR, 3d Sess., pt. 
1, at 71, U.N. Doc. A/810 (1948) [hereinafter Universal Declaration]; Charter of the Organization of 
American States, Apr. 30, 1948, 2 U.S.T. 2394, 119 U.N.T.S. 3 [hereinafter OAS Charter]; American 
Declaration of the Rights and Duties of Man, O.A.S. Res. XXX, OEA/Ser.L/V/I.4 Rev. (1965) 
[hereinafter American Declaration]; International Covenant on Civil and Political Rights, Dec. 19, 
1966, 999 U.N.T.S. 171, 6 I.L.M. 368 (entered into force for the United States Sept. 8, 1992) 
[hereinafter ICCPR]; International Covenant on Economic, Social and Cultural Rights, Dec. 16, 1966, 
993 U.N.T.S. 3, 6 I.L.M. 360 [hereinafter ICESCR]; U.N. CHARTER. See discussion infra  Part V. 
 15. A jus cogens norm is a peremptory, nonderogative norm that has the force of supreme law. 
Also known as customary international law, jus cogens status arises from (1) state practice, and (2) the 
fact that states practice this norm because they believe it is the law. See RESTATEMENT (THIRD) OF THE 
FOREIGN RELATIONS LAW OF THE UNITED STATES § 102 (1987) (describing the sources of 
international law, which include customary international law, international agreements, and general 
principles). Customary international law cannot be derogated by treaty, and states are automatically 
bound without state practice or consent. See LOUIS HENKIN ET AL., HUMAN RIGHTS 355 n.4 (1999).  
 16. But see Lt. Martin A. Harry, The Common Heritage of Mankind or Arena for Unilateral 
Exploitation?, 40 NAVAL L. REV. 207, 207-08 (1992) (noting that the Common Heritage of 
Humankind has a jus cogens status in a number of developing countries). However, given the 
strenuous objections of indigenious people groups to the practice of bioprospecting human cells, it is 
likely that the Common Heritage of Humankind jus cogens norm in certain developing countries does 
not encompass human genetic resources. See discussion infra  Part  IV.B (addressing concerns of 
indigenous people groups that bioprospecting activities threaten cultural values and concepts of 
individual sovereignty). 
Washington University Open Scholarship
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explores Moore v. Regents of the University of California17 and its 
implications for property rights of human genetic resources. Part IV 
addresses the Human Genome Diversity Project (HGDP) and the 
surrounding controversy. This section includes the background of the 
HGDP, as well as its Model Ethical Protocol, the instrument that the 
HGDP uses to obtain informed consent from indigenous people groups 
before extracting their cells. Part V discusses the United States’ obligation 
to adhere to various human rights instruments in order to safeguard 
fundamental human rights. This section will include descriptions of the 
Universal Declaration of Human Rights,18 the Charter of the Organization 
of American States,19 the American Declaration of the Rights and Duties 
of Man,20 the International Covenant of Civil and Political Rights,21 the 
International Covenant of Economic, Social and Cultural Rights,22 and the 
Charter of the United Nations.23 Finally, Part VI of this Note proposes that 
the United States enact legislation patterned after the HGDP Model 
Ethical Protocol in compliance with its human rights obligations under 
various international instruments in order to safeguard the fundamental 
human rights contained therein. 
I. BACKGROUND AND HISTORY 
A. The Development of Property Rights in Human Genetic Resources 
The expansion of the biotechnology24 industry escalated research in the 
biotech field, thereby increasing the measure of bioprospecting activities.25 
Under the principle of the Common Heritage of Humankind,26 
 
 
 17. 793 P.2d 479 (Cal. 1990). 
 18. Universal Declaration, supra  note 14. 
 19. OAS Charter, supra  note 14. 
 20. American Declaration, supra  note 14. 
 21. ICCPR, supra  note 14. 
 22. ICESCR, supra  note 14. 
 23. U.N. CHARTER. 
 24. Biotechnology encompasses “any process in which organisms, tissues, cells, organelles, or 
isolated enzymes are used to convert biological or other raw materials to products of greater values, as 
well as the design and use of reactors, fermenters, downstream processing, analytical and control 
equipment associated with biological manufacturing processes.” J. COOMBS, DICTIONARY OF 
BIOTECHNOLOGY 45 (1989). 
 25. See Daniel L. McKay, Patent Law and Human Genome Research at the Crossroads: The 
Need for Congressional Action, 10 SANTA CLARA COMPUTER & HIGH T ECH . L.J. 465 (1994). 
 26. The Common Heritage of Humankind is a principle that has been applied to “deep seabeds, 
Antarctica, and the Moon and other celestial bodies and certain worldwide historical sites” that gives 
all of humanity the benefit of use through the recognition that the “genome is integral to every human 
being.” Melissa L. Sturges, Who Should Hold Property Rights to the Human Genome? An Application 
https://openscholarship.wustl.edu/law_lawreview/vol78/iss3/6
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bioprospectors are free to exploit natural resources because, in the end, 
their actions benefit the whole world.27 The practice of bioprospecting is 
not limited to plant and animal resources; researchers have also patented 
cell-lines derived from excised human cells of indigenous people groups.28 
An example of cell extraction from indigenous people occurred in 1989 
when scientists removed cells from twenty-four members of the Hahahai 
tribe, located in Papua New Guinea, and discovered that a cell-line 
derivation could have potential value in “diagnosing adult leukemia and 
chronic degenerative neurologic disease.”29 The scientists submitted a 
patent application for the blood samples they derived from the tribe 
members.30 
Indigenous people groups are communities who “share customs and 
local knowledge of specific geographic territory and are relatively 
independent of, or have little contact with, the dominant national society 
of the country in which they live.”31 They are often the targets of scientific 
 
 
of the Common Heritage of Humankind, 13 AM. U. INT’L L. REV. 219, 223, 247-48 (1997). The 
United Nations has applied this principle under the rationalization that such “environmentally 
vulnerable sites” are not the sole subject of domestic sovereignty. Id. at 248. See also Lt. Martin A. 
Harry, The Deep Seabed: The Common Heritage of Mankind or Arena for Unilateral Exploitation?, 40 
NAVAL L. REV. 207, 207-08 (1992) (stating that the Common Heritage of Humankind has a jus cogens 
status in a number of developing countries).  
 27. Sturges argues that because the Common Heritage of Humankind confers a property right to 
all of humankind with regard to the genome of natural resources, the principle must also apply with 
regard to the human genome. See Sturges, supra  note 26, at 223-24. See also Jeremy Rifkin, The 
Biotech Century: Human Life as Intellectual Property, T HE NATION, Apr. 13, 1998, at 11 (describing 
the argument by nongovernmental organizations and countries that the “gene pool ought not to be for 
sale at any price—that it should remain an open commons and continue to be used freely by present 
and future generations”).  
 28. The exploitation of ethnobiological knowledge is an additional concern. Ethnobiological 
knowledge is the painstaking culmination of information about indigenous plants and animals passed 
down from generation to generation. It has been suggested that the use of ethnobiological knowledge 
on the part of bioprospectors should fall under trade secret laws in order to safeguard the rights of the 
indigenous people in this matter. See McManis, supra  note 12.  
 29. Hunter, supra note 6, at 139. 
 30. Id. 
 31. Edith Brown Weiss, IN FAIRNESS TO FUTURE GENERATIONS:  INTERNATIONAL LAW, 
COMMON PATRIMONY, AND INTERGENERATIONAL EQUITY  264 (1990). See also Naomi Roht-Arriaza, 
Of Seeds and Shamans: The Appropriation of the Scientific and Technical Knowledge of Indigenous 
and Local Communities, 17 MICH . J. INT’L L. 919, 921 (1996) (suggesting three frameworks to end 
“appropriation of indigenous and local communities’ knowledge and resources,” including “broadened 
and redefined intellectual property regimes, private contracts between communities or States and 
‘bioprospectors,’ and expansion of the concept of ‘farmers’ rights’ to provide both compensation and 
control to indigenous and local communities”). See generally Russel Lawrence Barsh, Indigenous 
Peoples: An Emerging Object of International Law, 80 AM. J. INT’L L. 369 (1986) (describing the 
difficulty of the members of The Working Group on Indigenous Populations, “an organ of the United 
Nations Sub-Commission on Prevention of Discrimination and Protection of Minorities,” to define 
“indigenous populations”).  
Washington University Open Scholarship
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research because the relative isolation of the communities ensures minimal 
gene flow.32 In another case, a San Diego biotech company collected cells 
from an island population on Tristan da Cunha, where over half of the 
people were asthmatics.33 Boehringer Ingelhiem, a German company, 
funded the research and purchased the resulting patent for $70 million.34 
Here, the inhabitants of the island of Tristan da Cunha were not considered 
indigenous, but the relative isolation of the population conferred the same 
kind of cell value from the perspective of the San Diego biotech 
company.35 
In Diamond v. Chakrabarty ,36 the United States Supreme Court made 
its first decision regarding patenting living organisms and held that a live 
human-made microorganism is patentable subject matter.37 A decade later, 
the California Supreme Court faced the weightier issue of property rights 
in human cells in the landmark case, Moore v. Regents of the University of 
California .38 Fully conscious of the implications of the issue, the court did 
 
 
 32. Genetic drift is a phenomenon composed of “irregular (random) fluctuations in gene 
frequency in a population from generation to generation due to finite population size (in ‘effectively’ 
small populations whose effective breeding size either remains small or periodically becomes small) or 
randomly fluctuating selection intensities.” R. RIGER ET AL., GLOSSARY OF GENETICS: CLASSICAL 
AND MOLECULAR 209 (5th ed. 1991). Gene flow is the movement of genes among populations, caused 
by movement of individuals prior to reproduction. Id. at 195. Therefore, gene flow can increase 
genetic variability in the population. Recombination, the phenomenon that occurs when differing 
genomes combine, results in ambiguous genetic markers, thereby making it difficult to track 
evolutionary lines. See id . at 411-12. Therefore, scientists value the relative isolation of indigenous 
people groups, where the minimal gene flow preserves a certain genetic marker. See generally Kara H. 
Ching, Note, Indigenous Self-Determination In an Age of Genetic Patenting: Recognizing an 
Emerging Human Rights Norm , 66 FORDHAM L. REV. 687 (1997).  
 33. Asthma-Related Gene Found in Study on Small Island, Firm Says, L.A. T IMES, May 21, 
1997, at A18. 
 34. Id. See also  Paul Salopek, Genes Offer Sampling of Hope and Fear, CHI. T RIB., Apr. 28, 
1997, at 8. 
 35. Ching, supra  note 32, at 687 n.1. 
 36. 447 U.S. 303 (1980). A microbiologist filed a patent claim on human-made, genetically 
engineered bacteria capable of breaking down multiple components of crude oil, a capability possessed 
by no naturally occurring bacteria. Id. at 303. The United States Supreme Court held that the bacteria 
was patentable subject matter because it constituted a “manufacture” or “composition of matter” 
within the meaning of 35 U.S.C. § 101 (1994), 447 U.S. at 309-10. 
 37. 447 U.S. 303. The United States Patent and Trademark Office Board of Appeals affirmed the 
decision of a patent examiner who found that bacteria were living things and therefore not patentable. 
The United States Court of Customs and Patent Appeals reversed, holding that the fact that 
microorganisms are alive is not relevant to the characterization of patentable subject matter. The 
United States Supreme Court affirmed. Justice Brennan was joined by Justices White, Marshall and 
Powell in his dissent, arguing that Congress had indicated its belief that prior statutes regulating the 
patenting of plants does not encompass living organisms. Id. See generally I. Jane Churchill, Patenting 
Humanity: The Development of Property Rights in the Human Body and the Subsequent Evolution of 
Patentability of Living Things, 8 INTELL. PROP. J. 249 (1994).  
 38. 793 P.2d 479 (Cal. 1990). 
https://openscholarship.wustl.edu/law_lawreview/vol78/iss3/6
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not assign the plaintiff property rights in the patented cell-line derived 
from his excised cells.39 The court rendered an uneasy decision, finding 
that the plaintiff’s complaint stated “a cause of action for breach of 
fiduciary duty, or lack of informed consent,” but not conversion.40 
Controversy began anew in 1991 when the Human Genome Diversity 
Project (HGDP) began to map the cell-lines of the 5,000 linguistically 
distinguishable people groups in the world.41 The HGDP’s goal to use the 
collected data for the benefit of all people by “preserv[ing] the record of 
our genetic heritage”42 has been met with hostile reaction by indigenous 
people groups who fear that the so-called “vampire project”43 will 
continue the pattern of developed countries feeding off unprotected 
developing countries.44 Several incidents further fueled the controversy, 
including the United States government’s applications for U.S. and 
international patents on viruses from cell-lines extracted from tribal 
members.45 When foreign governments lodged angry protests against what 
they perceived to be an invasion of “genetic privacy,”46 the United States 
withdrew its patent applications. 
In 1993, a researcher from the National Institute of Health (NIH) 
extracted a blood sample from a Guaymi Indian woman from Panama.47 
Upon developing a cell-line, the NIH found that the blood of Guaymi 
Indians contained a gene that conferred natural resistance to leukemia.48 
 
 
 39. Id. 
 40. Id. at 485. The Court limited Moore’s cause of action for a breach of fiduciary duty to the 
duty owed by the physician who extracted his cells. Moore had no cause of action against the 
researchers who developed the cell-line from his extracted cells because there was no contact between 
Moore and his physicians. Id. at 486. See also  Ching, supra  note 32, at 702, 704 (stating that “the 
doctrine of informed consent stems from a doctor’s duty to a patient and recognizes the patient’s right 
to self-determination and autonomy”). 
 41. See Rifkin, supra note 27. See also  Morrison Institute for Population and Resource Studies, 
The Human Genome Diversity Project, available at http://www.stanford.edu/group/morrinst/hgdp/ 
summary93.html (last visited Aug. 29, 2000).  
 42. See Whitt, supra  note 9, at 221. The scientists involved in HGDP are also anxious to collect 
data on indigenous people groups in danger of disappearing. Id. at 222.  
 43. Id. 
 44. Id. See also  Debra Harry, The Human Genome Diversity Project: Implications for Indigenous 
Peoples, (March 14, 1995) available at http://www.hartford-hwp.com/archives/41/024.html (last  
visited Aug. 29, 2000) (stating that indigenous groups should “call for a world-wide moratorium on the 
collection, databasing, transformation, and commercialization of cell lines and genetic materials of 
Indigenous peoples until international standards and regulation [sic] are put into place which fully 
protect the environment and the interests of Indigenous peoples”).  
 45. See Rifkin, supra  note 27. See generally Roht-Arriaza, supra  note 31, at 919 (describing 
examples of biotech corporations from developed countries whose patents of resources indigenous to 
developing countries brought great economic gain).  
 46. Rifkin, supra  note 27. 
 47. Id. 
 48. Id. 
Washington University Open Scholarship
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When representatives of the Guaymi General Congress in Panama 
discovered that the United States had filed for both U.S. and international 
patents on the virus developed from the cell-line, they publicly expressed 
their opinion against what they considered an invasion of their “genetic 
privacy.”49 The ensuing controversy caused the United States to withdraw 
its patent applications.50 
Nevertheless, “gene prospecting” continues, and technological 
developments have increased the rate of genome mapping greatly.51 U.S. 
companies have received broad patents granting ownership rights over 
human cells, including umbilical cord blood and bone-marrow stem 
cells.52 
B. Utility of Cell-Lines Derived from Human Cells 
The utility in developing cell-lines lies in the replicative ability of 
excised cells.53 Primary cells extracted directly from the body typically 
 
 
 49. Id. 
 50. Id. 
 51. See id. On April 6, 2000, Celera Genomics announced that it successfully completed the 
human genome sequencing phase and was ready to “assemble the sequenced fragments of the genome 
into their proper order based on new computational advances.” Celera Genomics Completes 
Sequencing Phase of the Genome from One Human Being, available at 
http://www.pecorporation.com/press/prccorp040600.html (last visited Oct. 31, 2000). See infra note 99 
and accompanying text (regarding the Human Genome Project (HGP) and the Human Genome 
Diversity Project (HGDP)). See also  Kathryn Brown, The Human Genome Business Today, SCI. AM., 
July 2000, at 50; Ken Howard, The Bioinformatics Gold Rush , SCI. AM., July 2000, at 58; Sharon 
Begley, Decoding the Human Body, NEWSWEEK, Apr. 10, 2000, at 50.  
 52. Rifkin, supra note 27. See also Jennifer Kulynych, Blood As A Biological “Drug”: Scientific, 
Legal, and Policy Issues in the Regulation of Placental and Umbilical Cord Stem Cell 
Transplantation, 32 U. RICH . L. REV. 407, 410-411 (1998) (recommending that the Food and Drug 
Administration (FDA) should treat umbilical cord blood as an “investigatory new drug subject to a 
period of clinical development,” because passing regulatory requirements would not adequately 
address the “ethical and scientific issues involved in cord blood transplantation”). In 1972, the FDA 
gained jurisdiction over biologics, or “products derived from living materials—humans, plants, 
animals, or microorganisms—when such products are used in the treatment or prevention of disease.” 
Id. at 421-22. See 37 Fed. Reg. 12,865 (June 23, 1972). After determining that biologics were subject 
to the same regulatory provisions as applied to drugs or medical devices (Investigational New Drug 
process), the FDA could require a showing of “clinical effectiveness prior to marketing.” 32 U. RICH. 
L. REV. at 422-23. However, such an investigation could prove needless if cord blood stem cells are 
“well-characterized blood products” and not “investigational” drugs. Id. at 426. Kulynych states that 
the unresolved “safety and efficacy” issues necessitate an investigation approach to cord blood 
products, as protected by the IND process, which includes “qualified investigators, informed consent, 
institutional review board approval of protocols, and detailed tracking and reporting of clinical 
outcomes.” Id. at 430 (emphasis added). See also  Stephen R. Munzer, The Special Case of Property 
Rights in Umbilical Cord Blood for Transplantation, 51 RUTGERS L. REV. 493 (1999) (arguing that 
there should be limited property rights in umbilical cord blood).  
 53. The human body is composed of cells that contain chromosomes. Every person normally has 
a total of twenty-three pairs of chromosomes in each cell. Chromosomes contain thousands of genes, 
https://openscholarship.wustl.edu/law_lawreview/vol78/iss3/6
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replicate a few times before dying. However, when developed into a 
culture, cells may replicate indefinitely, thus creating an immortal cell-
line.54 Therefore, a cell-line allows scientists to continue their research 
efforts without immediately depleting their supply of genetic material.55 
Cell-lines also enable scientists to conduct their experiments under 
controlled circumstances.56 
C. Mechanics of the Patenting Process 
In order to apply successfully for a United States patent, the applicant 
must fulfill five general requirements: that the invention “[(1)] falls within 
the broad category of patentable subject matter, (2) is novel, (3) is non-
obvious, (4) has utility, and (5) is adequately disclosed.”57 
The United States Supreme Court extended patent protection to living 
microorganisms for the first time in Diamond v. Chakrabarty .58 
Subsequent to that decision, the United States continued to expand the 
category of patentable subject matter to include DNA sequences of 
proteins.59 The United States Patent and Trademark Office has also issued 
life patents, which have been upheld by the Supreme Court.60 
 
 
which are the functional units that code hereditary traits. Genes store information in tightly 
compressed strands of deoxyribonucleic acid (DNA), which is a paired linear sequence of four distinct 
molecular bases: adenine, thymine, cytosine, and guanine. The human genome is the genetic 
information in each cell and contains approximately six billion base pairs of DNA. Because humans 
have approximately six billion base pairs of DNA, decoding the human genome is an ambitious task. 
Symposium, Probing the Human Genome: Who Owns Genetic Information?, 4 B.U. J. SCI. & TECH. 
L. 2 (1998). See generally Catherine M. Valerio Barrad, Genetic Information and Property Theory, 87 
NW. U. L. REV. 1037 (1993) (discussing the increasing interest in the human genome). For a more 
technically descriptive explanation of genetics, see ANTHONY J.F. GRIFFITHS ET AL., AN 
INTRODUCTION TO GENETIC ANALYSIS (6th ed. 1996); BRUCE ALBERTS ET AL., MOLECULAR 
BIOLOGY OF THE CELL (3d ed. 1994).  
 54. Moore v. Regents of the University of California, 793 P.2d 479, 481 n.2 (Cal. 1990). 
 55. See Jean de Vellis, Ownership of Cell Lines, 65 S. CAL. L. REV. 697 (1991) (discussing the 
development and use of cell-lines). 
 56. See Ching, supra note 32, at  690. Goals for genetic research include the detection of genetic 
defects, the production of proteins for those afflicted with a genetic defect that causes protein 
production inhibition, and the discovery of cures for general medical diseases. Id. at 690-91. See also 
Geoffrey Cowley & Anne Underwood, A Revolution in Medicine, NEWSWEEK, Apr. 10, 2000, at 58 
(describing how genetic knowledge could impact medical treatment). 
 57. McKay, supra note 25 at 479. 35 U.S.C. § 101 provides the requirements for patentable 
subject matter, novelty, and utility. 35 U.S.C. § 102 provides the non-obviousness requirement. 35 
U.S.C. § 112 provides the disclosure requirement. Id. 
 58. 447 U.S. 303 (1980). 
 59. See Ching, supra  note 32, at 696. 
 60. See id. Life patents include patents on cell-lines derived from humans. Id. See McKay, supra 
note 25, at 495 (suggesting that a moratorium on patenting life forms would “create a bright-line rule 
that would be easy for courts to apply, [but] a ban on such patents might destroy the United States 
biotechnology industry, which is projected to have world-wide sales in excess of $100 billion by the 
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The novelty requirement, the claim that the product has never been 
made accessible to the general public, necessarily excludes those products 
that are naturally occurring in the public domain, for example, certain 
chemical processes in the human body.61 The product must be non-
obvious, that is, it must demonstrate an “inventive step” that makes the 
product distinguishable from all others.62 Additionally, the product must 
have a useful function,63 a somewhat vague and subjective requirement. 
Lastly, the inventor must give complete disclosure on how to manufacture 
the product in order to be granted the right to exclude others from 
manufacturing the product.64 
On its face, cell-lines are subject to the United States patent process: 
the researcher claiming inventorship of the product may disclose the 
method by which the excised cells were developed into a cell-line, a 
method that calls for some amount of scientific ingenuity; the uniqueness 
of the cell-line can be easily proven by its very nature; and functionality 
can be proven by the resulting scientific data.65 
D. The Growing Implications of Bioprospecting 
The granting of ownership interest in human cells, albeit limited to the 
twenty-year span of a U.S. patent,66 has caused great concern for those 
who unwittingly donate their cells without fully understanding the 
implications of their actions.67 As bioprospecting activities escalated, it 
became evident that private companies were gaining massive profits with 
little or no positive return for the source countries.68 The discovery that 
bioprospectors were extracting cells in order to patent the resulting cell-
lines without first obtaining informed consent from the indigenous people 
promulgated an ideological shift away from the Common Heritage of 
Humankind philosophy69 to a more protective concern for the rights of the 
 
 
year 2000”). 
 61. See Symposium, Probing the Human Genome: Who Owns Genetic Information?, 4 B.U. J. 
SCI. & T ECH . L. 2, ¶ 14 (1998). 
 62. Id. at ¶ 15. 
 63. See id. at ¶ 16. 
 64. See id. at ¶ 12. 
 65. See JAMES BOYLE, SHAMANS, SOFTWARE , AND SPLEENS: LAW AND THE CONSTRUCTION OF 
THE INFORMATION SOCIETY , 21-24, 97-107 (Harvard University Press 1996). 
 66. TRIPS Agreement, supra  note 11, art. 33. 
 67. Boyle, supra  note 65, at 21-24. 
 68. See supra  note 9 and accompanying text. 
 69. See supra  notes 26-27 and accompanying text (describing the Common Heritage of 
Humankind principle). 
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indigenous people groups.70 
II. THE BIODIVERSITY CONVENTION AND THE TRIPS AGREEMENT 
In response to this growing concern over the wanton exploitation of 
natural resources of developing countries, the United Nations formulated 
the Convention on Biological Diversity (Biodiversity Convention). 
Entering into force in 1993, the Biodiversity Convention includes 
provisions compensating source countries for the use of their natural 
resources. Constructed out of a concern for the conservation of natural 
resources, the Biodiversity Convention primarily addresses bioprospecting 
activities involving plants, animals, and microorganisms.71 A year later, 
the United Nations formulated the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS Agreement). The TRIPS Agreement seeks to 
promote world trade by regulating international intellectual property 
rights72 and nation-to-nation agreements to protect the rights of indigenous 
people groups. 
Under Article 1 of the Biodiversity Convention, the Convention’s three 
objectives are: (1) the conservation of biological diversity, (2) the 
sustainable use of its components, and (3) the fair and equitable sharing of 
the benefits arising out of the utilization of genetic resources.73 The third 
objective includes “appropriate access to genetic resources and . . . 
appropriate transfer of relevant technologies.”74 The Bush Administration 
interpreted this to mean that nations are required to make a technology 
transfer in order to access the genetic resources of the developing 
countries.75 However, because the phrase “genetic resources” is defined as 
“genetic material,” which in turn “means any material of plant, animal, 
microbial, or other origin containing functional units of heredity,”76 the 
Biodiversity Convention fails to apply clearly to the cell-lines patented by 
biotech companies. A vague reference to indigenous people occurs in 
Article 8(j), in which contracting parties must, among other things, 
“encourage the equitable sharing of the benefits arising from the utilization 
of . . . [the] knowledge, innovations and practices [of indigenous and local 
 
 
 70. See, e.g., Hunter, supra  note 6, at 138-41. 
 71. Biodiversity Convention, supra  note 7. 
 72. TRIPS Agreement, supra  note 11. See also  McManis, supra  note 12. 
 73. Biodiversity Convention, supra  note 7. 
 74. Boyle, supra  note 65, at 21. 
 75. Curtis M. Horton, Protecting Biodiversity and Cultural Diversity Under Intellectual Property 
Law: Toward a New International System , 10 J. ENVTL. L. & LITIG. 1 (1995). 
 76. Biodiversity Convention, supra  note 7. 
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communities].”77 Although this language could be interpreted to mandate 
adequate compensation for the indigenous people subjected to 
bioprospecting activities, the Biodiversity Convention has been severely 
criticized for its general and vague provisions, which fail to bring about 
effective regulation.78 
In contrast, the TRIPS Agreement has a more definite influence on 
intellectual property rights through the establishment of international 
minimum standards to bring about “adequate and effective patent 
protection”79 as well as “minimum standards for civil and criminal 
penalties and associated judicial procedures.”80 Article 27 of the TRIPS 
Agreement concerns patentable subject matter, and provides that members 
may exclude from patentability “diagnostic, therapeutic and surgical 
methods for the treatment of humans or animals” as well as “plants and 
animals other than microorganisms, and essentially biological processes 
for the production of plants or animals other than non-biological and 
microbiological processes.”81 Criminal procedures, outlined in Article 61, 
are applicable “at least in cases of willful trademark, counterfeiting or 
copyright piracy on a commercial scale.”82 
III. THE IMPLICATIONS OF MOORE V. REGENTS OF THE UNIVERSITY OF 
CALIFORNIA 
The United States Patent and Trademark Office (USPTO) announced 
in April 1987 that “nonnaturally occurring non-human multicellular living 
organisms, including animals,”83 were now considered to be patentable 
subject matter. It stopped short of including humans, however, because 
doing so would violate the United States Constitution by granting a 
“limited, but exclusive property right in a human being.”84 Even so, the 
resulting criticism caused the USPTO to impose a moratorium on animal 
patents, in effect until September 30, 1987. Congress then held hearings 
 
 
 77. Biodiversity Convention, supra  note 7, at art. 8(j). 
 78. See Horton, supra  note 75, at 23-24. 
 79. McManis, supra note 12, at 267. 
 80. Horton, supra  note 75, at 25. 
 81. TRIPS Agreement, supra  note 11, art. 27. 
 82. Id. at art. 61. See also Horton, supra  note 75, at 26. 
 83. Commissioner of Patents, Nonnaturally Occurring Non-Human Animals are Patentable 
Under Section 101, 33 PAT. T RADEMARK & COPYRIGHT J. (BNA) 664 (1987). This policy change 
stemmed from the United States Supreme Court’s groundbreaking holding in Diamond v. 
Chakrabarty, 447 U.S. 303 (1980), that recognized non-human organisms as patentable subject matter. 
 84. Patents and the Constitution: Transgenic Animals: Hearings Before the Subcomm. on 
Courts, Civil Liberties, and the Administration of Justice, 100th Cong., 1st Sess. 22 (1987) (statement 
of Commissioner Donald Quigg). 
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during which the House Agricultural Committee proposed that the USPTO 
be prevented from “issuing animal patents until the moral, ethical and 
economic implications were thoroughly explored by Congress.”85 
The immediate alarm occasioned by the prospect of patenting animals 
is rooted in a deeper concern that it might lead to the patenting of human 
traits.86 However, the relatively recent exercise and ultimate rejection of 
the practice of slavery,87 a definitive example of the commodification of 
humans as commercial entities, negates this slippery slope argument.88 
Nevertheless, the basic question of property rights over the human 
genome remains unresolved. Little case law exists on the issue, and even 
less legislative activity. In the landmark case, Moore v. Regents of the 
University of California ,89 John Moore was diagnosed with hairy-cell 
leukemia, and underwent treatment at the University of California Los 
Angeles. During the course of treatment, Moore’s physicians discovered 
that Moore’s blood contained components that presented “competitive, 
commercial, and scientific advantages.”90 Although it remained unclear as 
to whether it was medically necessary to do so, Moore’s physicians 
extracted samples of Moore’s blood, sperm, and other bodily fluids.91 
They also removed his spleen and arranged for portions of it to be sent to a 
laboratory for research purposes.92 When Moore discovered that a cell-line 
extracted from his excised cells had been patented—its worth in 1990 
estimated to be upwards of three billion dollars—he sued the Regents of 
California, his physicians, and the researchers involved in the cell-line 
development for, inter alia, the tort of conversion.93 The California 
Supreme Court evaluated the conversion charge by examining the 
sensitive area of property rights to one’s own cells.94 In the end, the court 
did not assign any property rights to the plaintiff regarding the patented 
cell-line and the conversion cause of action failed. However, the court held 
 
 
 85. Keith Schneider, Agency and Congress Face Clash Over Patenting of Animals, N.Y. TIMES, 
July 23, 1987, at A17. See also  Hoffmaster, infra note 86, at 2.  
 86. See Barry Hoffmaster, The Ethics of Patenting Higher Life Forms, 4 INTELL. PROP. J. 1, 11 
(1988). 
 87. See, e.g., ICCPR, supra  note 14, art. 8(1) (providing that “[n]o one shall be held in slavery; 
slavery and the slave trade in all their forms shall be prohibited”); RESTATEMENT (T HIRD) OF THE 
FOREIGN RELATIONS LAW OF THE UNITED STATES § 702 (1987) (“A state violates international law if, 
as a matter of state policy, it practices, encourages, or condones . . . (b) slavery or slave trade.”). 
 88. Id. 
 89. 793 P.2d 479 (Cal. 1990). 
 90. Id. at 481. 
 91. Id. 
 92. Id. 
 93. Id. at 482. 
 94. Id. at 487-88. 
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that the physicians owed a fiduciary duty to Moore, which they had 
breached by not advising him of their research interest in his cells.95 
Moore’s small victory, then, was based on the strength of an informed 
consent argument rather than a bright-line resolution of the question of 
property rights to human cells.96 The court agreed with the argument that 
assigning property rights would severely hamper the important progress of 
medical research.97 
IV. THE HUMAN GENOME DIVERSITY PROJECT (HGDP) AND THE 
SURROUNDING CONTROVERSY 
A. Background of the HGDP 
The California Supreme Court’s treatment of the question of property 
rights in one’s own genetic resources resonated in 1991 when Dr. Luigi 
Luca Cavalli-Sforza, emeritus professor of genetics at Stanford University, 
proposed what is now known as the Human Genome Diversity Project 
(HGDP).98 The HGDP is an offshoot of the Human Genome Project 
(HGP).99 The HGP is a $3 billion, international effort to map and sequence 
every gene in the human body—a total of approximately one hundred 
thousand genes—within a fifteen-year period ending in the year 2003. In 
contrast, the HGDP is a $25 million to $30 million dollar project, which 
attempts to map and sequence a smaller number of genes from indigenous 
people groups in order to study human migration across cultural 
boundaries within a five-year period.100 This is a crucial difference 
 
 
 95. See supra  note 40 and accompanying text (describing the California Supreme Court’s 
decision regarding Moore’s cause of action for a breach of fiduciary duty). 
 96. See Moore, 793 P.2d at 497. 
 97. See id . at 497. 
 98. Morrison Institute for Population and Resource Studies, The Human Genome Diversity 
Project, available at http://www.stanford.edu/group/morrinst/hgdp/summary 93.html (last visited Aug. 
29, 2000). 
 99. The Human Genome Project (HGP) is not to be confused with the Human Genome Diversity 
Project (HDGP). The HGP is supported by the Human Genome Organization (HUGO), though private 
corporations have largely taken over. The HGDP is a nongovernmental organization that is made up of 
researchers around the world. See Barrad, supra note 53; Sturges, supra note 26; Mitchell Leslie, The 
History of Everyone and Everything, STANFORD MAGAZINE (May/June 1999), available at 
http://www.stanfordalumni.org/jg/mig/news_magazine/magazine/mayjun99/articles/cavalli_sforza.htm
l (last visited Aug. 31, 2000); Rifkin, supra note 27.  
 100. The fact that indigenous people groups tend to intermarry facilitates the gene tracking, but 
the HGDP is not limited to small, disappearing tribes. Instead, it spans the 85% of the world 
population that has a non-European origin, which includes large people groups that account for 
millions of people (e.g., Han Chinese, the Yoruba and Fulani in Nigeria). See, e.g., David Perlman, A 
Search Among Vanishing Peoples: Genetic Sleuths Race Against Time, S.F. CHRONICLE, Apr. 21, 
1993, at A1 (noting that “Cavalli-Sforza’s project hopes to trace the paths our ancestors have taken 
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between the HGDP and the HGP, because the latter project collects and 
maps cells from primarily European subjects.101 In 1993, conscious of the 
concern for the rights of the indigenous people groups, HGDP 
representatives met in a planning workshop to discuss major issues, 
including informed consent.102 The representatives agreed that informed 
consent was a crucial component of the project, privacy would be 
protected, and the project would not have commercial ties.103 
B. The HGDP Model Ethical Protocol 
Despite these promises, the HGDP has been inundated with protests 
accusing the project of fostering biocolonialism from indigenous people 
groups and organizations that safeguard the rights of indigenous people.104 
 
 
since they first radiated outward from mankind’s birth place”). See also Leslie, supra note 99; Dorothy 
C. Wertz, The DNA Ancestree (Sept. 1, 2000), available at http://www.geneletter.com/09-01-
00/features/prn_ancestreea.html (last visited Oct. 30, 2000). See also  Nathaniel Pearson, My Blood 
Brother in Samarkand, STANFORD MAGAZINE (May/June 1999) (describing a Stanford student’s visit 
to a Samarkand man’s home upon discovering that they shared a recent male-line ancestor), available 
at http://www.stanfordalumni.org/jg/m...jun99/articles/dna_detectives.html (last  visited Aug. 30, 
2000). Researchers involved in the HGDP hope that this comprehensive look at the human genome 
will reveal valuable information about the human body and further biomedical research. See infra note 
101 and accompanying text (arguing that the HGP may result in erroneous conclusions about what is 
“normal,” given that at least 70% of the world’s population is omitted from project consideration).  
 101. An example of how it is significant that the HGP uses European subjects, whereas the HGDP 
uses subjects from a variety of ethnic groups, may be found in the fact that most people of European 
origin are lactose tolerant, whereas 70% of the world population is lactose intolerant. LACTOSE 
INTOLERANCE , available at http://healthcastle.com/herb_lact.shtml (last visited Oct. 30, 2000). See 
also NATIONAL DIGESTIVE DISEASES INFORMATION CLEARINGHOUSE ,  WHAT IS LACTOSE 
INTOLERANCE? (“As many as 75% of all African-Americans and Native Americans and 90% of Asian-
Americans are lactose intolerant. The condition is least common among persons of northern European 
descent.”), available at http://niddk.nih.gov/health/digest/pubs/lactose/lactose.htm#whatis (last visited 
Oct. 30, 2000). This cultural and genetic predisposition may be one of many that the HGP fails to 
address. Such omissions may significantly affect the “normal standard” scientists hope to derive from 
the mapping and sequencing of the entire human genome. Therefore, there is a risk that the HGP may 
arrive at erroneous conclusions. Wertz, supra  note 100.  
 102. HENRY T. GREELY, Informed Consent, Stored Tissue Samples, and the Human Genome 
Diversity Project: Protecting the Rights of Research Participants, in STORED T ISSUE SAMPLES: 
ETHICAL, LEGAL AND PUBLIC POLICY IMPLICATIONS 89, 93 (Robert F. Weir ed., 1998). Greely is a 
Stanford Law School ethicist who chairs the HGDP’s ethics subcommittee. See Leslie, supra note 99. 
See generally Net Resources Relating to the Human Genome Diversity Project, available at 
http://www.ratical.org/co-globalize/HumanGenomeP.html (last visited Oct. 30, 2000). 
 103. Greely, supra  note 102, at 93. 
 104. See Leslie, supra  note 99. Anthropologist Jon Marks described a 1992 meeting “where 
anthropologists, linguists, geneticists and archaeologists selected roughly 500 populations [to study]” 
without inviting any representatives of these populations in order to “try to get blood out of natives’ 
veins and into Palo Alto as expeditiously as possible.” Id. But see Morrison Institute for Population 
and Resource Studies, supra  note 98. The HGDP prompted an Australian aboriginal group to call it a 
“vampire project.” See Leslie, supra  note 99. See Paul Salopek, Basically, We Are All the Same: 
Controversial Genetic Quest is Unlocking Secrets of the Human Rainbow, CHI. TRIB., Apr. 27, 1997, 
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There were concerns that the project would result in patented commercial 
products derived from their cells, which would then be sold back to the 
developing countries for a great profit.105 Such an arrangement was all too 
common when biotechnology companies from developed countries 
extracted plant and animal cells to manufacture products, which they in 
turn sold for a profit to developing countries. 
In order to preserve cultural sensitivity, the HGDP representatives 
formulated a protocol for ethical principles that delineated procedures for 
contacting source populations, including: obtaining informed consent,106 
providing medical services, maintaining privacy and confidentiality, and 
resolving questions of ownership and control.107 The protocol specified 
that prior to extracting new samples, the informed consent of the 
individual donor—as well as, in some cases, the informed consent of the 
group—must be obtained. Groups would be able to limit the use of the 
 
 
at C1 (describing the indignant reaction of Nilo Cayugueo, a Mapucke Indian from Argentina and the 
director of the Abya Yala Fund: “‘Imagine the arrogance of coming in and giving tribal people a 
machete or 15 bucks for their blood, then telling them, “well, you’re from so-and-so place 1,000 years 
ago . . . .” Who are they to tell us where we came from? Don’t they understand that’s sacrilegious?’”). 
See generally Rifkin, supra  note 27. There are also general concerns that “knowledge of an 
individual’s genetic makeup can lead to insurance and employment discrimination.” Sturges, supra 
note 26, at 226.  
 105. See generally Victoria Tauli-Corpuz, Biotechnology and Indigenous People, THIRD WORLD 
NETWORK  (arguing that the Human Genome Diversity Project “is still the appropriation of what 
[indigenous peoples] have and even of what [they] are, not just for the sake of science but for more 
profits”), available at http://twnside.org.sg/title/tokar.htm (last visited Aug 31, 2000). Patents, 
Indigenous Peoples, and Human Genetic Diversity (May 30, 1993), available at 
http://64.4.69.14/web/allpub-display.shtml?pf1=com-list-en.param (last visited Oct. 30, 2000). Other 
concerns include the suggestion by the Rural Advancement Foundation International (RAFI), a non-
governmental international organization based in Canada that “promotes sustainable agriculture and 
works to protect intellectua l property rights of indigenous people,” that the data on “population-
specific traits” could be developed into biological weapons used to commit genocide. Leslie, supra 
note 99. See generally RAFI: RURAL ADVANCEMENT FOUNDATION INTERNATIONAL, available at 
http://www.rafi.org/ (last visited Aug. 30, 2000). Cavalli-Sforza counters these concerns by stating that 
the HGDP has no intention to patent DNA and that population groups aren’t vulnerable to custom-
made biological weapons since “most genetic differences are between individuals, not groups.” Leslie, 
supra  note 99. See also Morrison Institute for Population and Resource Studies, HGDP Frequently 
Asked Questions,  (stat ing that “[g]enocidal use of genetics is not possible with any currently known 
technology” and that the HGDP would deplore the use of its data for such purposes), available at 
http://www.stanford.edugroup/morrinst/hgdp/faq.html (last visited Aug. 30, 200). See generally U.N. 
CHARTER, arts. 55-56; Universal Declaration of Human Rights at 71.  
 106. But see Victoria Tauli-Corpuz, Biotechnology and Indigenous Peoples, T HIRD WORLD 
NETWORK  (expressing doubt that the “process of informed consent” will be thoroughly  followed, 
“considering the time constraints imposed by the proponents on themselves . . . . For such a 
controversial project there is a strong possibility that informed consent will not be applied as it should 
be”), available at http://www.twnside.org.sg/title/tokar.htm (last visited Oct. 31, 2000). 
 107. See Proposed Model Ethical Protocol for Collecting DNA Samples, 33 HOUS. L. REV. 1431 
(1997). 
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samples108 and confidentiality would be carefully controlled. The protocol 
also outlined a culturally-sensitive approach to the form of consent by 
acknowledging, for example, that some cultures are averse to signing 
contract documents.109 
V. U.S. OBLIGATIONS TO SAFEGUARD HUMAN RIGHTS UNDER 
INTERNATIONAL LEGAL INSTRUMENTS 
The issue of informed consent in bioprospecting practices invariably 
raises intellectual property concerns.110 Although amendments to the 
Biodiversity Convention or the TRIPS Agreement regarding informed 
consent could solve many problems related to bioprospecting,111 the 
human element invokes fundamental implications outside of mere 
possession. The assigned rights within the “principal postwar human rights 
instruments are framed in terms of individual rights.”112 A survey of these 
individual rights causes serious concern regarding the ethics of 
bioprospecting activities without obtaining informed consent.113 
 
 
 108. See Greely, supra note 102, at 101. 
 109. Proposed Model Ethical Protocol for Collecting DNA Samples, supra  note 107. 
 110. See, e.g., McManis, supra  note 12 (exploring the interface between international intellectual 
property and environmental protection in order to reconcile the conflicts within the Biodiversity 
Convention and the TRIPS Agreement); McKay, supra  note 25; Roht-Arriaza, supra note 31, 
(suggesting three frameworks for ending “appropriation of indigenous and local communities’ 
knowledge and resources,” including “broadened and redefined intellectual property regimes”). 
 111. See McManis, supra note 12; Nuno Pires de Carvalho, Requiring Disclosure of the Origin of 
Genetic Resources and Prior Informed Consent in Patent Applications Without Infringing the TRIPS 
Agreement: The Problem and the Solution, 2 WASH . U. J.L. & POL’Y 371 (2000) (suggesting that a 
“requirement that the origin of genetic resources and prior informed consent be disclosed in patent 
applications, as proposed by different countries in at least two different international fora” can be 
“adopted by [World Trade Organization] Members at the national, regional or internat ional levels 
without infringing the TRIPS Agreement”).  
 112. LOUIS HENKIN ET AL., HUMAN RIGHTS 426 (1999). Although the principal human rights 
instruments in existence today arose out of the atrocities of World War II and the “Nazi persecution of 
victims targeted because of their membership in such minority groups as Jews, homosexuals, and 
Roma and Sinti communities,” the human rights instruments were drafted out of a desire to affirm the 
fundamental rights of every individual human being rather than concentrate on the rights of minority 
groups. Id. at 427. Therefore, although this Note focuses on indigenous people groups of developing 
countries as the primary targets of bioprospecting activities, the principle behind the proposal to enact 
legislation to protect their human rights should be attributed to an overall concern for the rights of all 
people. 
 113. This Note does not postulate whether or not the United States is in violation of the various 
international legal instruments of which it is a party. Rather, this Note suggests that bioprospecting 
activities without the benefit of informed consent invokes serious human rights questions that should 
be answered by domestic legislation. 
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A. The Universal Declaration of Human Rights 
The Universal Declaration of Human Rights provides, “All human 
beings are born free and equal in dignity and rights.”114 In addition, 
“Everyone is entitled to all the rights and freedoms set forth in [The 
Universal Declaration of Human Rights], without distinction of any kind, 
such as race, colour, sex, language, religion, political or other opinion, 
national or social origin, property, birth or other status.”115 Article 22 
provides that every person, “as a member of society . . . is entitled to 
realization, through national effort and international co-operation . . . of 
the economic, social and cultural rights indispensable for his dignity and 
the free development of his personality.”116 
B. The American Declaration of the Rights and Duties of Man 
As a member of the Organization of American States,117 the United 
States is obliged to follow the American Declaration of the Rights and 
Duties of Man,118 which recognizes that “[a]ll men are born free and equal, 
in dignity and in rights, and, being endowed by nature with reason and 
conscience, they should conduct themselves as brothers one to another.”119 
In addition to the right to life, liberty, and personal security,120 the United 
States is required to recognize and protect the right to protection of honor, 
personal reputation, private and family life,121 the right to work and to fair 
remuneration,122 and the right to recognition of juridical personality and of 
 
 
 114. Universal Declaration, supra  note 14, art. 1. 
 115. Id. at art. 2. 
 116. See id . at art. 22; Horton, supra  note 75, at 29-30. 
 117. Every sovereign state of the Americas, including the United States, is a party to the 
Organization of the American States (OAS). However, although all OAS parties are parties to the 
American Declaration of the Rights and Duties of Man, not all OAS parties are parties to the American 
Convention on Human Rights, Nov. 22, 9 I.L.M. 673. See generally LOUIS HENKIN ET AL., HUMAN 
RIGHTS 342-43, 523, 784 (1999). As of 1999, the United States is not a party to the American 
Convention. However, “[i]t may no longer be accurate to conclude that American states not party to 
the American Convention . . . are not subject to any human rights obligations in the American system.” 
Id. at 343 n.1.  
 118. The American Declaration of the Rights and Duties of Man is considered an “authoritative 
interpretation” of the Charter of the Organization of American States and “may also have contributed 
to customary law.” See HENKIN, supra  note 117, at 343 n.1. However, “[i]t is generally accepted that 
the American Declaration was not intended to have legally binding character.” Id. at 342. 
 119. American Declaration, supra  note 14, pmbl. 
 120. “Every human being has the right to life, liberty and the security of his person.” American 
Declaration, supra  note 14, at art. I. 
 121. “Every person has the right to the protection of the law against abusive attacks upon his 
honor, his reputation, and his private and family life.” American Declaration, supra note 14, at art. V. 
 122. “Every person has the right to work, under proper conditions, and to follow his vocation 
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civil rights.123 These rights recognize the inherent value of a person by 
endowing each individual with protection over his or her person, and 
validate a person’s actions, whether it is establishing a family or following 
a vocation. Significantly, the United States must recognize an individual’s 
identity as a “person having rights and obligations,”124 independent of 
geography. The primary qualification is personhood.125 
C. The International Covenant on Civil and Political Rights 
Under the International Covenant on Civil and Political Rights 
(ICCPR), the United States must “respect and . . . ensure to all individuals 
within its territory and subject to its jurisdiction the rights recognized”126 
in the ICCPR. Once the United States ratifies the ICCPR, relevant 
provisions in the treaty include a right of self-determination,127 a right to 
not be subjected to medical or scientific experimentation without 
consent,128 and the right to the “inherent dignity of the human person.”129 
 
 
freely, insofar as existing conditions of employment permit.” American Declaration, supra note 14, at 
art. XIV. 
 123. “Every person has the right to be recognized everywhere as a person having rights and 
obligations, and to enjoy the basic civil rights.” American Declaration, supra  note 14, at art. XVII. 
 124. See id . at art. XVII (giving every person a right “to be recognized everywhere as a person 
having rights and obligations”). 
 125. The American states have . . . recognized that the essential rights of man are not derived from 
the fact that he is a national of a certain state, but are based upon attributes of the human personality; 
[t]he international protection of the rights of man should be the principal guides of an evolving 
American law.” American Declaration, supra  note 14, pmbl. 
 126. ICCPR, supra  note 14, at art. 2(1). The United States became a party to the ICCPR in 1992 
under the significant declaration that the treaty was not self-executing. This means that U.S. courts will 
not accept the t reaty if Congress has not passed complementing legislation. See generally HENKIN, 
supra  note 117, at 323.  
It is commonly accepted that “within its territory and subject to its jurisdiction” was intended 
to mean “those within its territory and those otherwise subject to its jurisdiction.” . . . The 
State is obligated to respect the rights of persons not within its territory but nevertheless 
subject to the State’s jurisdiction, whether because they are national of the State, or residents 
temporarily outside the territory, or even generally, perhaps because the State Party reaches 
out beyond its territory to exercise jurisdiction over them. 
Id. In the case of researchers from U.S. biotech companies who visit developing countries and extract 
cells from individuals belonging to indigenous people groups, the United States may be obliged to 
follow the ICCPR provisions if: (1) the United States exercises jurisdiction over the individual, and (2) 
the United States ratifies the ICCPR. 
 127. “All peoples have the right of self-determination. By virtue of that right, they freely 
determine their political status and freely pursue their economic, social and cultural development.” 
ICCPR, supra  note 14, at art. 1(1).  
 128. “No one shall be subjected to torture or to cruel, inhuman or degrading treatment or 
punishment. In particular, no one shall be subjected without his free consent to medical or scientific 
experimentation.” ICCPR, supra  note 14, at art. 7. 
 129. Id. at art. 10. “All persons deprived of their liberty shall be treated with humanity and with 
respect for the inherent dignity of the human person.” Id. Although the context of this provision is loss 
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D. The International Covenant on Economic, Social and Cultural Rights 
The International Covenant on Economic, Social and Cultural Rights 
(ICESCR)130 mimics the ICCPR in guaranteeing a right to self-
determination.131 A significant provision states that “[n]othing in the 
present Covenant shall be interpreted as impairing the inherent right of all 
peoples to enjoy and utilize fully and freely their natural wealth and 
resources.”132 Although the United States has historically assigned 
property rights to genetic resources, it is worth noting that an individual 
cannot take the genetic resources of another individual—blood, cells, or 
tissue—without violating the right to self-determination and every other 
right that defines an individual as an autonomous human being.133 
E. The United Nations Charter 
According to the United Nations Charter, all member-nations should 
collectively promote “universal respect for, and observance of, human 
rights and fundamental freedoms for all,” which “all Members pledge 
themselves to take joint and separate action” to achieve.134 Therefore, 
noting the human rights obligations of the United States under the 
international law instruments previously discussed,135 the United States is 
bound, if not merely by law, then by conscience, to safeguard the rights of 
indigenous people groups it exploits through its bioprospecting activities. 
 
 
of liberty, it is important to note that the preservation of human dignity remains an underlying value. 
 130. Although the language of the ICESCR is “softer” in obligating state parties “to the maximum 
of its available resources,” the ICESCR nonetheless establishes legally binding obligations. See 
ICESCR, supra  note 14, at art. 2 (“Each State Party to the present Covenant undertakes to take steps, 
individually and through international assistance and cooperation, especially economic and technical, 
to the maximum of its available resources, with a view to achieving progressively the full realization 
of the rights recognized in the present Covenant by all appropriate means, including particularly the 
adoption of legislative measures.”). See also  HENKIN, supra  note 117, at 329. 
 131. “All peoples have the right of self-determination. By virtue of that right they freely determine 
their political status and freely pursue their economic, social and cultural development.” ICESCR, 
supra  note 14, at art. 1(1). 
 132. Id. at art. 25. 
 133. See HENKIN, supra  note 117, at 88 (describing the inclusion of self-determination provisions 
in the ICCPR and ICESCR, thereby characterizing self-determination as a human right, despite 
arguments that it was merely a political right). 
 134. See U.N. CHARTER, arts. 55-56; Horton, supra  note 75, at 29. 
 135. See discussion supra  Part V.A.-V.D. 
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VI. PROPOSAL 
A. The Utility of Informed Consent and Adequate Compensation 
The Moore136 decision and a technical application of U.S. patent 
regulations treat the human body as a “naturally occurring raw material” 137 
that possesses no property rights to excised cells. But informed consent 
becomes the saving grace; it transforms the human from a mere repository 
of genetic material, subject to the big-picture importance of scientific 
research,138 into a “sovereign individual with an unchallengeable 
entitlement to the facts necessary to make informed decisions.”139 
The Biodiversity Convention fails to speak directly to the indigenous 
people groups whose cells are excised without compensation, and the 
phrase “at least” in Article 61 of the TRIPS Agreement140 is too weak to 
support the weighty human rights implications of patenting human cells 
without informed consent. Therefore, both the Biodiversity Convention 
and the TRIPS Agreement afford inadequate protection to the matter at 
hand because they lack any serious treatment of the patenting of cell-lines 
derived from extracted cells of indigenous people groups. 
Given the United Nations mandate to safeguard the fundamental 
freedom of human dignity, the United States should adhere to the United 
Nations Charter and its other international treaties141 by implementing 
domestic legislation to protect the fundamental human rights of self-
determination142 and “the inherent dignity of the human person.”143 
 
 
 136. 793 P.2d 479 (Cal. 1990). 
 137. See Boyle, supra  note 65, at 106. 
 138. An argument against the patenting of human cells posits that it hampers medical research by 
requiring scientists to pay the holder of the patent fees in order to utilize the patented matter. See 
Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in 
Biomedical Research, SCI. MAG., May 1, 1998, at 698 (discussing how intellectual property rights 
increases have led to an “anticommons,” where scarce resources are underused because “too many 
owners can block each other”). See also  Thomas P. Dillon, Source Compensation for Tissues and Cells 
Used in Biotechnical Research: Why A Source Shouldn’t Share in the Profits, 64 NOTRE DAME L. 
REV. 628 (1989) (stating that public policy considerations argue against unlimited property rights in 
human tissues and cells because the resulting competitive bidding will increase the costs of developing 
the product); Robert Heidt, Maintaining Incentives for Bioprospecting: The Occasional Need for a 
Right to Lie, 13 BERKELEY T ECH . L.J. 667 (1998) (arguing that lying to a patient about the value of his 
cells will allow a researcher to obtain the patient’s consent to collect valuable cells more easily). 
 139. See Boyle, supra  note 65, at 107. 
 140. See discussion supra  Part III. 
 141. The International Covenant of Civil and Political Rights and the International Covenant of 
Economic, Social and Cultural Rights are two such treaties to consider. 
 142. ICCPR, supra  note 14, at art. 1.1; ICESCR, supra  note 14, at art. 1.1.  
 143. ICCPR, supra  note 14, at art. 10.1. 
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Informed consent is the primary exercise of sovereignty that humans have 
over their own bodies; a failure to regulate the patenting of human cells by 
way of procuring informed consent relegates the human body to a mere 
natural resource, robbed of a soul. Congress should implement legislation 
to safeguard the rights of indigenous people by mandating informed 
consent. Such a provision would cure the flaws of both the Biodiversity 
Convention and the TRIPS Agreement and prevent the patenting of human 
cells. Necessity obviates the need for such regulation144 because, 
historically, the United States has abandoned such patents only after a 
public outcry by foreign governments.145  
Although some critics deem a protocol for delineating the issue of 
obtaining informed consent an unrealistic undertaking,146 the need for the 
construction of such regulation supersedes the cultural morass. The 
Human Genome Diversity Project, for example, drafted a thirty-five page 
ethical protocol not to prevent the exploitation of the indigenous people 
groups specifically, but to benefit all humans generally.147 Therefore, the 
HGDP’s “Proposed Model Ethical Protocol for Collecting DNA Samples” 
(HGDP Ethical Protocol) is a useful model for the proposed international 
agreement.148 
The HGDP Ethical Protocol purports to use a culturally sensitive 
approach to all aspects of collecting cell samples from indigenous people 
groups. This approach includes preparation before contact as well as 
during contact with the population, and the details of obtaining informed 
consent. These details include identifying the person from whom consent 
 
 
 144. See Dorothy C. Wertz, The Human Genome Diversity Project (HGDP), THE GENE LETTER 
(Nov. 1996) (stating that “[o]utside the United States, Canada, the United Kingdom, and Western 
Europe, there are few procedures for ethical review, and researchers can proceed without informed 
consent and may use genetic material for commercial purposes”), available at 
http://www.geneletter.org/1196/hgdp.html (last visited July 25, 2000) (on file with the author). Since 
the HGDP purports to elicit international adherence to ethical protocols from researchers all over the 
world, opponents to the HGDP may “inadvertently increase the very exploitation they are trying to 
prevent.” Id. 
 145. Symposium, Probing the Human Genome: Who Owns Genetic Information?, 4 B.U. J. SCI. 
& T ECH . L. 2 (1998); Rifkin, supra note 27. 
 146. Symposium, supra note 53. But see Dorothy C. Wertz, The Human Genome Diversity Project 
(HGDP), T HE GENE LETTER (Nov. 1996) (stating that individual researchers unrelated to the HGDP 
who have patented human genes without consent are examples of “what can happen in the absence of 
international agreement to an ethical protocol”), available at http://www.geneletter.org/1196/ 
hgdp.html (last visited July 25, 2000) (on file with the author). 
 147. See Symposium, supra note 53, at ¶ 74 (noting that the “NIH’s official agenda is to promote 
public health, not exploit indigenous people”). See Sturges, supra  notes 26-27 and accompanying text 
(arguing that the Common Heritage of Humankind principle should be applied to the international 
regulation of genome use). 
 148. Symposium, International Health Law Model Protocol, 33 HOUS. L. REV. 1431 (1997). 
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should be obtained, the timing of obtaining consent, the characterization of 
what constitutes “informed consent,” and the manifest form of the consent. 
Concerns regarding the ability to relate to a culturally foreign group are 
rooted in what could be perceived as legal niceties that lack cultural 
counterparts due to untranslatable concepts and values. The HGDP Ethical 
Protocol mandates honesty and seeks an amenable understanding of what 
is culturally appropriate as a solution to such a difficulty. Human nature is 
the common ground by which all international agreements operate 
successfully, not language or national custom. 
So too should the proposed legislation of this Note operate from the 
premise of shared humanity. It should urge the eventual acceptance as a 
fundamental norm both informed consent and adequate compensation of 
indigenous people groups by developed countries and developing 
countries alike. The objective of the legislation is to safeguard the rights of 
the indigenous people while preserving the integrity of scientific research. 
The economic benefits of bioprospecting are not worth the violation of the 
fundamental human right to self-determination and inherent dignity. 
In order to facilitate a practical relationship with the indigenous people 
groups, bioprospectors must be thoroughly familiar with the language and 
customs of the people. It is not cultural sensitivity that will stifle scientific 
progress, but the alienating and dehumanizing effects of an invasion of 
genetic privacy. 
An informed consent should be obtained from every individual from 
whom cells are extracted through hair samples, blood, and other bodily 
fluids. If the individual is still viewed as a child by the indigenous society, 
bioprospectors must obtain permission from the child’s caretakers. Family 
units must be respected. In addition to an individual informed consent, 
bioprospectors must obtain the informed consent of the governing body of 
the indigenous group. The governing body may be made up of a single 
leader or a small number of select individuals. 
Informed consent must be obtained prior to any extraction of cells. This 
may be done before entering the territory of the indigenous people group, 
so as to build up a mutual trust, or it may be done after entering the 
territory. Should consent be requested and refused after the extraction, 
both parties have suffered needlessly: the bioprospector from effort and 
expense, and the indigenous individual from an invasion of privacy. 
Therefore, clear consent must be secured to prevent useless transactions. 
Informed consent should be made up of three essential parts: (1) the 
nature and risks of the indigenous individual’s participation (the pledge 
that the extraction process will be performed in a safe, sanitary manner 
with little risk to the indigenous individual is necessary to the contract 
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between bioprospector and the indigenous individual); (2) the nature of the 
extraction and of the scientific study, including the expected utility of the 
study; and (3) expected actions with regard to the extracted cells (e.g., 
developing a cell-line, mere storage for research purposes). 
The way informed consent is to be transmitted may have varying levels 
of difficulty. The transaction must be recorded in a way that is legally 
recognized by the governments of both parties. Any mode of record 
allowable by the indigenous people (e.g., video recorders, tape recorders) 
may be used. 
Similar to Article 61 of the TRIPS Agreement, which provides for 
criminal procedures applicable in “cases of willful trademark 
counterfeiting or copyright piracy on a commercial scale,”149 the proposed 
international agreement for patenting cell-lines of indigenous people 
groups would include criminal procedures for cases of willful extraction 
without obtaining informed consent. The crime would necessitate an actus 
reus finding—the extraction of human cells—and a mens rea element—
the intentional failure to obtain informed consent. Remedies for such cases 
may range from civil penalties to imprisonment, in addition to the seizure 
and destruction of the “infringing goods and of any materials and 
implements the predominant use of which has been in the commission of 
the offense.”150 
CONCLUSION 
The oddity of patenting human cells has aggravated and fueled much 
hysterical controversy, not without good cause. It is ironic that the 
painstaking research and backbreaking innovation involved in revealing 
the secrets of human history and the mysteries of human futurity are often 
met with the fear that this quasi-philanthropy dehumanizes its proposed 
beneficiary. Whether or not that is true is left unresolved; however, the 
struggle to safeguard the fundamental human rights of indigenous people 
groups through, inter alia, adequate compensation, begs the question: 
what is the basis of the transaction? A sense of fairness obviates the need 
to pay for what we buy; that is, the genetic resources we have extracted 
and utilized in the name of medical research. If the compensation is based 
on property right, then the Pandora’s Box of biological, philosophical, 
ethical, and spiritual chaos is opened and may never be closed again. 
However, if the compensation is based upon a simpler idea, namely the 
 
 
 149. TRIPS Agreement, supra  note 11. 
 150. Id. 
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preservation of human sovereignty over personal dignity and individual 
freedoms, then so too should every human action be regulated. Far better 
than the so-called Golden Rule,151 the motivation to pursue our nobler 
objectives without compromising that which makes us human only 
lengthens the reaches we may go. 
Annie O. Wu* 
 
 
 151. “So in everything, do to others what you would have them do to you, for this sums up the 
Law and the Prophets.” Matthew 7:12 (New International Version). 
 * A.B. (1997), Stanford University; J.D. Candidate (2001), Washington University School of 
Law. 
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